Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 24:12:579448.
doi: 10.3389/fpsyt.2021.579448. eCollection 2021.

Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study

Wei Hua  1 , Sen Wang  2 , Xi Wang  1 , Ying Shao  1 , Yali Wang  1 , Jiangzhu Ye  1 , Bin Su  1 , Taiyi Jiang  1 , Tong Zhang  1 , Hao Wu  1 , An Liu  1 , Qunhui Li  1 , Supriya D Mahajan  3 , Zaicun Li  1 , Lijun Sun  1 , Lili Dai  1
Affiliations

Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study

Wei Hua et al. Front Psychiatry. .

Abstract

Background: Efavirenz (EFV) is widely used in antiretroviral therapy (ART), but the incidence and risk factors of neuropsychiatric adverse events (NPAEs) after EFV treatment have rarely been studied in Chinese ART naïve patients. Methods: This prospective cohort study assessed HIV-infected patients initiating antiretroviral treatment with EFV to determine prevalence of and factors associated with NPAEs over a 12-month follow-up period using the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Results: A total of 546 patients were enrolled. Prevalence of anxiety, depression, and sleep disturbances at baseline were 30.4, 22.7, and 68.1%, respectively. Six patients discontinued treatment due to drug related NPAEs. Treatment was associated with improvements in HADS-A, HADS-D, and PSQI scores over the 12-month follow-up, and the frequencies of patients with anxiety, depression, and sleep disturbances significantly decreased after 12 months. Abnormal baseline HADS-A, HADS-D, and PSQI scores and other factors, including high school education or lower income, unemployment, divorce, and WHO III/IV stages, were associated with severe neuropsychiatric disorders over the 12 months. Conclusions: These findings suggested EFV discontinuation due to NAPEs was low, and the HADS-A, HADS-D, and PSQI scores after 12 months of EFV treatment were associated with several risk factors. The clinicians should keep in mind and routinely screen for the risk factors associated with neuropsychiatric disorders in HIV-infected patients.

Keywords: antiretroviral therapy; anxiety; depression; efavirenz; sleep disturbances.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewers SS and JC declared a shared affiliation with the authors SM and SW respectively, to the handling editor at the time of review.

Figures

Figure 1
Figure 1
Flow chart of subject enrolment.
Figure 2
Figure 2
The trend of changes in the PSQI (A), HADS-D (B), and HADS-A (C) scores over the 12-months follow-up period. Graphs show the mean values and SDs at each trimester. Comparison between two groups was performed by paired t-tests. p < 0.05 was considered statistically significant. *: 0.01 < p < 0.05 compared to M0; **: 0.001 < p < 0.01 compared to M0; ***p < 0.001 compared to M0. PSQI, Pittsburgh Sleep Quality Index; HADS-D, Hospital Anxiety and Depression Scale-Depression subscale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale; M, month. Dots: individuals with normal HADS-A, HADS-D, or PSQI scores at baseline. Squares: individuals with abnormal HADS-A, HADS-D, or PSQI scores at baseline.
Figure 3
Figure 3
Frequency and severity of depression (A), anxiety (B), and sleep disturbance (C) at each time point in patients with HIV infection. Comparison of depression, anxiety and sleep disturbance rates between paired groups was performed by the McNemar test. Comparison of severity between two groups was performed by Chi-square test. p < 0.05 was considered significant. *: 0.01 < p < 0.05 compared to M0; **: 0.001 <p < 0.01 compared to M0; ***p < 0.001 compared to M0.
See this image and copyright information in PMC

References

    1. WHO Guidelines Approved by the Guidelines Review Committee . Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; (2016). - PubMed
    1. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS ONE. (2013) 8:e68995. 10.1371/journal.pone.0068995 - DOI - PMC - PubMed
    1. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. (2001) 345:398–407. 10.1056/NEJM200108093450602 - DOI - PubMed
    1. Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. (2006) 368:287–98. 10.1016/S0140-6736(06)69074-0 - DOI - PubMed
    1. Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. (2014) 28(Suppl. 2):S123–31. 10.1097/QAD.0000000000000231 - DOI - PubMed

LinkOut - more resources